Biotech | May 02, 2022
Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical
Avacc 3 has significant advantages over existing whooping cough vaccines
Avacc 3 has significant advantages over existing whooping cough vaccines
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
Clobetasol Propionate Foam, 0.05% has an estimated market size of US $ IO million for twelve months ending Dec 2021 according to IQVIA
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
All the capex is being met through internal accruals only
The proposed life sciences research and development centre in North of England region of UK will support acceleration of the company’s research in the areas of biotechnology, health and life sciences
Ivabradine Tablets, 5 mg and 7.5 mg have an estimated market size of US $ 102 million for twelve months ending December 2021 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
